The hospital infection therapeutics market is expected to grow to $3.6 billion by 2020, which may be good news for long-term care residents in need of treatment.
Infections acquired in hospitals don’t stay there, and residents arriving for post-acute care can have urinary tract infections, gastrointestinal disorders or bloodstream infections. The market was around $3 billion in 2013, and trending upwards, according to the Transparency Market Research report.
The antibacterial drugs’ share of the hospital infection therapeutics market is expected to develop most swiftly over the next four years, according to the report. While hospital-acquired pneumonia represented more than 20% of the market in terms of infection rates, UTIs are expected to grow at an even faster rate.
The prominent players in the market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson & Johnson Services Inc., Sanofi, and Pfizer Inc.
The report, titled “Hospital Infection Therapeutics Market — Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014-2020,” is available for purchase here.
